A Cohort Study of Use of Doravirine (DOR) Based Regimens in Clinical Practice in Europe DoRavirine Europe Real World/

Inclusion Criteria: * are HIV positive male or female * are aged ≥18 years * were prescribed and received at least one dose of DOR (without initial dose adjustment). * have started/been switched to DOR for at least 12 months at time of data collection * had a resistance genotype available before starting DOR Cohort 1 Specific Inclusion Criteria * had no evidence of DOR-associated resistance mutation * were on DOR containing ART regimen that also contained 2 fully active nucleos(t)ides and patient had no documented NRTI resistance mutations to the two NRTIs in the combination. * Patients who, at the time of initiation, were: 1. Category 1: HIV treatment naïve OR 2. Category 2: Virologically suppressed (HIV-1 RNA \<50 copies/mL) for at least 6 months with no evidence of prior virological failure with agents of the NNRTI class Patients in category 1 and 2 above who have NNRTI mutations that do not impact on DOR (K103N, Y181C, and G190A) using the Stanford algorithm (https://hivdb.stanford.edu/hivdb/by-mutations) can be included in this study. Cohort 2 Specific Inclusion Criteria * must have evidence of NNRTI associated resistance mutations (other than DOR) according to Stanford algorithm * their DOR-containing ART will contain 2 NRTIs but will not include an INSTI and/or a bPI. * had no documented resistance to the other drugs in the combination. * Patients who, at the time of initiation, were: 1. Category 1: HIV treatment naïve OR 2. Category 2: Virologically suppressed (HIV-1 RNA \<50 copies/mL) for at least 6 months Cohort 3 Specific Inclusion Criteria * ART naïve or virologically suppressed (HIV-1 RNA \<50 copies/mL) for at least 6 months at the time of DOR initiation Exclusion Criteria: * Patients with no documented resistance testing. * Patients with no genotype available at DOR initiation * Patients enrolled in DOR trials Cohort 1 specific exclusion criteria * Patients who have DOR as part of their fourth line or higher therapy * Patients with prior virological failure with agents of the NNRTI class Cohort 2 specific exclusion criteria * Patients who have an INSTI and/or bPI in their DOR-containing therapy * Patients who have NNRTI mutations that impact on DOR